At the 2021 prestigious conference of the American Association of Cancer Research (AACR), Curesponse presented findings that could drive significant progress in how the medical community selects cancer treatments. New interim clinical trial results, which were collected in collaboration with physicians from Sheba, Kaplan, Hadassah and Beilinson hospitals in Israel, show Curesponse’s technology can predict the response to cancer treatment at an accuracy of between 87% and 96%.
Menu